Collegium Pharmaceutical (COLL) Price to Sales (2016 - 2026)

Collegium Pharmaceutical has reported Price to Sales for 11 years, with the latest figure at 5.89 in Q2 2026.

• On a quarterly basis, Price to Sales rose 18.61% year-over-year to 5.89 in Q2 2026; TTM through Jun 2026 was 1.46, a 10.31% increase from a year earlier, with the FY2025 full-year figure at 1.88, up 31.84% from the prior year.
• Price to Sales was 5.89 for Q2 2026 at Collegium Pharmaceutical, up from 5.54 in the prior quarter.
• The five-year high for Price to Sales was 8.76 in Q1 2024, with the low at 4.26 in Q3 2022.
• Average Price to Sales over 5 years is 6.06, with a median of 5.56 recorded in 2026.
• The sharpest annual moves came in 2022 and 2024: Price to Sales slumped 75.7% in 2022, then surged 52.88% in 2024.
• Over 5 years, Price to Sales stood at 5.58 in 2022, then grew by 17.33% to 6.55 in 2023, then retreated by 24.42% to 4.95 in 2024, then surged by 44.34% to 7.15 in 2025, then decreased by 17.63% to 5.89 in 2026.
• The last three Price to Sales figures came in at 5.89 (Q2 2026), 5.54 (Q1 2026), and 7.15 (Q4 2025), per Business Quant data.